Brief: Lumos Diagnostics Holdings Says Febridx Has Not Been Granted Clearance For Marketing In U.S
03/10/2022 02:28
Oct 3 (Reuters) - Lumos Diagnostics Holdings Ltd
LDX.AX :
* FEBRIDX HAS NOT BEEN GRANTED CLEARANCE FOR MARKETING IN US
* INTENDS TO DIRECT ITS EFFORTS FOR COMMERCIALISING FEBRIDX
IN
MARKETS WHERE IT HAS BEEN ALREADY BEEN GRANTED CLEARANCE
Source text for Eikon: ID:nASX2Q9vQP
Further company coverage: LDX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Diagnostics Holdings
See all newsBrief: Lumos Diagnostics Posts FY26 Revenue Of $13.2 Million
Australia's Lumos Diagnostics soars on bagging purchase order for diagnostic test
Brief: Lumos Diagnostics Receives $767,800 Febridx Order From Phase Scientific
Brief: Lumos Diagnostics Signs Exclusive Distribution Agreement For Febridx In Romania
Brief: Lumos Diagnostics Posts FY26 Revenue Rises 6% To $13.2 Million